Project Details
Description
A Pahse 1 Open Label Dose Escalation Trial of QPI-1007 Delivered by Single Intravitreal Injection to Patients with Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Optic Neuropathy (NAJON) (Stratum II)
| Status | Finished |
|---|---|
| Effective start/end date | 2/15/10 → 2/14/13 |
Funding
- QUARK PHARMACEUTICALS, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.